Elucidation of bone-destroying diseases by controlling inflammatory cytokine

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K21372
• Project/Area Number (Other): 18H06283 (2018)
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund (2019); Single-year Grants (2018)
• Review Section: 0907:Oral science and related fields
• Research Institution: Keio University
• Principal Investigator: MORITA Mayu 慶應義塾大学, 医学部(信濃町), 助教 (30624639)
• Project Period (FY): 2018-08-24 – 2021-03-31
• Keywords: 破骨細胞 / 炎症性サイトカイン

Outline of Final Research Achievements

Animal models for osteonecrosis of the jaw have been reported; however, most of them have focused on the administered anti-bone resorptive drugs. We considered that oral bacteria may cause osteonecrosis based on its specific occurrence in the jawbone. Therefore, we established a new mouse model of osteonecrosis of the jaw associated with drug administration similar to that in human, and analyzed by using the model. The results suggested that inflammatory cytokines produced in macrophages due to bacterial infection may cause osteoclastic diseases,as typified by osteonecrosis. These results suggest that if the mechanism of anti-inflammatory action by cytokine regulation in the field of oral and maxillofacial surgery can be clarified, it may lead to new treatment methods for inflammatory diseases in the field of oral and maxillofacial surgery.

Free Research Field

骨代謝

Academic Significance and Societal Importance of the Research Achievements

口腔内の炎症を伴う骨破壊性疾患である顎骨壊死のヒトに近似した動物モデルの確立は、メカニズムの研究や治療法の開発には欠かせない．原因は、未だ解明されておらず、臨床医は治療方針の決定に難渋している。また、ビスフォスフォネート製剤が、骨粗鬆症の治療にとどまらず、様々な病態に広く使用されていることから、顎骨壊死の患者数は多い。現在治療法として行われている、外科的治療アプローチに代わる新しい治療戦略が求められており、新たな治療戦略の可能性を見出す可能性のある本研究内容は極めて重要であると考えている．